Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
about
An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivoThe renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.Clinical case studies in heart failure management.Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy.Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment valuesCilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study.Spironolactone in congestive heart failure.New perspectives on the role of aldosterone excess in cardiovascular disease.Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.The role of angiotensin II receptor blockers in the treatment of heart failure patients.Aldosterone and aldosterone antagonism in systemic hypertension.Aldosterone and cardiovascular remodelling: focus on myocardial failure.Eplerenone in the treatment of chronic heart failure.Prevalence and prognostic significance of adrenergic escape during chronic beta-blocker therapy in chronic heart failure.Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high saltComparative assessment of angiotensin receptor blockers in different clinical settings.Spironolactone management of resistant hypertension.Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 InhibitorsSpironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channelsAngiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy.Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats.Aldosterone-receptor antagonism and end-stage renal disease.Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results.Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats.Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.Anaesthesia for Conn's syndrome.Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
P2860
Q28578913-BC6C62A0-4241-419A-8F79-A026A73AD880Q30439734-FD9382E3-C075-476A-AD75-BEFA4760BA4CQ33601339-2A3B0544-CC43-4FE5-99F5-0E1D7B3946B9Q33645941-73402C50-A768-4151-8E6B-5DFB9F63C543Q33738790-40691CCC-D6AC-476A-8B84-FCCB14C7ABD8Q33739040-DCF17CAA-F79E-4D98-8754-1621D7A70456Q34038051-7CD00297-3F12-4E2F-937A-D340350BEF05Q34366011-DF13BB22-9226-4250-B54F-8A77770A7B0DQ34925428-62CC1FB8-8F43-4E7C-A89C-4493CEF9D046Q34995025-AA4DE111-6250-4A4C-9278-C0F0B32E3265Q35056228-1CD0C71F-172A-4974-9F40-09DF9016510FQ35765159-084FC900-395E-4908-999D-29AB3BE04817Q35770232-82B9461C-0920-4780-8F24-23050C3D6527Q35777385-683DFAAB-C453-4569-94C9-ABF3F432CC76Q37091005-A042B7AF-8DEE-4CE0-B497-39C80307760FQ37406166-6D26354B-F056-4166-BEE5-034EE1971410Q37649519-01F41B24-245E-47F9-A05E-B56AE7ACF8C1Q37803301-7B707523-066F-426E-9AB1-EDA2A10DB64CQ39768900-8E2B2BB4-260D-48ED-A496-19BD79C94E63Q40404466-03DE8436-1627-4C99-94B4-6AC30A6E1AB5Q42371966-B278DCB1-E71D-4CD5-8AE1-ECA5317A5729Q43063224-8EF3BABA-6D81-424F-9DAE-EE86F57EA421Q44361936-0006051C-B1E9-4ED0-BA12-78CD63A75390Q44903644-7D074393-D5A7-4D7C-B05B-B3B679C02216Q46160863-B283A66A-81FD-4A89-A479-0978F241F517Q46634232-5E48F25A-E4E6-4960-9369-1A65546C0621Q50925186-D9CC5578-1426-4385-B923-F29D3E633E61Q51451352-CF0DEA9E-86B5-4463-81BB-67819A85E443Q58795411-300655FD-0118-40C7-B761-765DE0A99A5D
P2860
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
@en
type
label
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
@en
prefLabel
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
@en
P356
P1476
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
@en
P2093
Struthers AD
P304
P356
10.1093/EURHEARTJ/16.SUPPL_N.103
P478
16 Suppl N
P577
1995-12-01T00:00:00Z